These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
191 related items for PubMed ID: 39367409
1. Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma. Wei E, Mitanoska A, O'Brien Q, Porter K, Molina M, Ahsan H, Jung U, Mills L, Kyba M, Bosnakovski D. Mol Cancer; 2024 Oct 05; 23(1):222. PubMed ID: 39367409 [Abstract] [Full Text] [Related]
2. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK. Oncotarget; 2015 Oct 06; 6(30):28895-910. PubMed ID: 26336820 [Abstract] [Full Text] [Related]
3. EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. Shimizu R, Tanaka M, Tsutsumi S, Aburatani H, Yamazaki Y, Homme M, Kitagawa Y, Nakamura T. Cancer Sci; 2018 Sep 06; 109(9):2907-2918. PubMed ID: 29945296 [Abstract] [Full Text] [Related]
6. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma. Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H. Oncogene; 2014 Jul 24; 33(30):3927-38. PubMed ID: 23995784 [Abstract] [Full Text] [Related]
9. Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma. García-Domínguez DJ, Hajji N, Sánchez-Molina S, Figuerola-Bou E, de Pablos RM, Espinosa-Oliva AM, Andrés-León E, Terrón-Camero LC, Flores-Campos R, Pascual-Pasto G, Robles MJ, Machado I, Llombart-Bosch A, Magagnoli G, Scotlandi K, Carcaboso ÁM, Mora J, de Álava E, Hontecillas-Prieto L. Oncogene; 2021 Sep 24; 40(39):5843-5853. PubMed ID: 34345016 [Abstract] [Full Text] [Related]
10. High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. He T, Surdez D, Rantala JK, Haapa-Paananen S, Ban J, Kauer M, Tomazou E, Fey V, Alonso J, Kovar H, Delattre O, Iljin K. Gene; 2017 Jan 05; 596():137-146. PubMed ID: 27760381 [Abstract] [Full Text] [Related]
11. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA. Sci Signal; 2017 Oct 03; 10(499):. PubMed ID: 28974650 [Abstract] [Full Text] [Related]
12. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells. El Beaino M, Liu J, Wasylishen AR, Pourebrahim R, Migut A, Bessellieu BJ, Huang K, Lin PP. BMC Cancer; 2020 Jan 02; 20(1):3. PubMed ID: 31898537 [Abstract] [Full Text] [Related]
13. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis. Ma Y, Baltezor M, Rajewski L, Crow J, Samuel G, Staggs VS, Chastain KM, Toretsky JA, Weir SJ, Godwin AK. J Mol Med (Berl); 2019 Jul 02; 97(7):957-972. PubMed ID: 31025088 [Abstract] [Full Text] [Related]
14. EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma. Jiménez JA, Apfelbaum AA, Hawkins AG, Svoboda LK, Kumar A, Ruiz RO, Garcia AX, Haarer E, Nwosu ZC, Bradin J, Purohit T, Chen D, Cierpicki T, Grembecka J, Lyssiotis CA, Lawlor ER. Mol Cancer Res; 2021 Jul 02; 19(7):1182-1195. PubMed ID: 33741715 [Abstract] [Full Text] [Related]
15. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma. Apfelbaum AA, Wu F, Hawkins AG, Magnuson B, Jiménez JA, Taylor SD, Wrenn ED, Waltner O, Pfaltzgraff ER, Song JY, Hall C, Wellik DM, Ljungman M, Furlan SN, Ryan RJH, Sarthy JF, Lawlor ER. Clin Cancer Res; 2022 Oct 14; 28(20):4466-4478. PubMed ID: 35653119 [Abstract] [Full Text] [Related]
16. EWS-FLI1 and Activator Protein-1 (AP-1) Reciprocally Regulate Extracellular-Matrix Proteins in Ewing sarcoma Cells. Croushore EE, Stipp CS, Gordon DJ. Int J Mol Sci; 2024 Aug 06; 25(16):. PubMed ID: 39201282 [Abstract] [Full Text] [Related]
17. MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor. Franzetti GA, Laud-Duval K, Bellanger D, Stern MH, Sastre-Garau X, Delattre O. Oncogene; 2013 Aug 15; 32(33):3915-21. PubMed ID: 22986530 [Abstract] [Full Text] [Related]
18. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Grohar PJ, Segars LE, Yeung C, Pommier Y, D'Incalci M, Mendoza A, Helman LJ. Clin Cancer Res; 2014 Mar 01; 20(5):1190-203. PubMed ID: 24277455 [Abstract] [Full Text] [Related]
19. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, Wang J. Oncotarget; 2016 Jul 12; 7(28):43504-43517. PubMed ID: 27259270 [Abstract] [Full Text] [Related]
20. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A, Toretsky JA. Proc Natl Acad Sci U S A; 2015 Mar 17; 112(11):E1307-16. PubMed ID: 25737553 [Abstract] [Full Text] [Related] Page: [Next] [New Search]